European candidaemia is characterised by notable differential
epidemiology and susceptibility pattern: Results from the
ECMM Candida III study

J 2023

European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study

ARENDRUP, Maiken Cavling, Sevtap ARIKAN-AKDAGLI, Karin Meinike JORGENSEN, Aleksandra BARAC, Jorg STEINMANN et. al.

Basic information

Original name

European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study

Authors

ARENDRUP, Maiken Cavling, Sevtap ARIKAN-AKDAGLI, Karin Meinike JORGENSEN, Aleksandra BARAC, Jorg STEINMANN, Cristina TOSCANO, Valentina Arsic ARSENIJEVIC, Assunta SARTOR, Cornelia LASS-FLOERL, Axel HAMPRECHT, Tadeja MATOS, Benedict R S ROGERS, Inmaculada QUILES, Jochem BUIL, Volkan OZENCI, Robert KRAUSE, Matteo BASSETTI, Laura LOUGHLIN, Blandine DENIS, Anna GRANCINI, P Lewis WHITE, Katrien LAGROU, Birgit WILLINGER, Riina RAUTEMAA-RICHARDSON, Petr HAMAL, Beyza ENER, Tugce UNALAN-ALTINTOP, Ebru EVREN, Suleyha HILMIOGLU-POLAT, Yasemin OZ, Ozlem Koyuncu OZYURT, Faruk AYDIN, Filip RŮŽIČKA (203 Czech Republic, belonging to the institution), Eelco F J MEIJER, Jean Pierre GANGNEUX, Deborah E A LOCKHART, Nina KHANNA, Clare LOGAN, Ulrike SCHARMANN, Guillaume DESOUBEAUX, Emmanuel ROILIDES, Alida Fe TALENTO, van Dijk KARIN, Philipp KOEHLER, Jon SALMANTON-GARCIA, Oliver A CORNELY and Martin HOENIGL

Edition

JOURNAL OF INFECTION, LONDON, W B SAUNDERS CO LTD, 2023, 0163-4453

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30303 Infectious Diseases

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 28.200 in 2022

RIV identification code

RIV/00216224:14110/23:00133411

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.jinf.2023.08.001

UT WoS

001103177000001

Keywords in English

Candida; C. parapsilosis; Fluconazole resistance; Echinocandin resistance; Fks1; EUCAST

Abstract

V originále

The objectives of this study were to assess Candida spp. distribution and antifungal resistance of candi-daemia across Europe. Isolates were collected as part of the third ECMM Candida European multicentre observational study, conducted from 01 to 07-07-2018 to 31-03-2022. Each centre (maximum number/ country determined by population size) included-10 consecutive cases. Isolates were referred to central laboratories and identified by morphology and MALDI-TOF, supplemented by ITS-sequencing when needed. EUCAST MICs were determined for five antifungals. fks sequencing was performed for echinocandin re-sistant isolates. The 399 isolates from 41 centres in 17 countries included C. albicans (47.1%), C. glabrata (22.3%), C. parapsilosis (15.0%), C. tropicalis (6.3%), C. dubliniensis and C. krusei (2.3% each) and other species (4.8%). Austria had the highest C. albicans proportion (77%), Czech Republic, France and UK the highest C. glabrata proportions (25-33%) while Italy and Turkey had the highest C. parapsilosis proportions (24-26%). All isolates were amphotericin B susceptible. Fluconazole resistance was found in 4% C. tropicalis, 12% C. glabrata (from six countries across Europe), 17% C. parapsilosis (from Greece, Italy, and Turkey) and 20% other Candida spp. Four isolates were anidulafungin and micafungin resistant/non-wild-type and five resistant to micafungin only. Three/3 and 2/5 of these were sequenced and harboured fks-alterations including a novel L657W in C. parapsilosis. The epidemiology varied among centres and countries. Acquired echinocandin resistance was rare but included differential susceptibility to anidulafungin and micafungin, and resistant C. parapsilosis. Fluconazole and voriconazole cross-resistance was common in C. glabrata and C. parapsilosis but with different geographical prevalence.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Citovat

ARENDRUP, Maiken Cavling, Sevtap ARIKAN-AKDAGLI, Karin Meinike JORGENSEN, Aleksandra BARAC, Jorg STEINMANN, Cristina TOSCANO, Valentina Arsic ARSENIJEVIC, Assunta SARTOR, Cornelia LASS-FLOERL, Axel HAMPRECHT, Tadeja MATOS, Benedict R S ROGERS, Inmaculada QUILES, Jochem BUIL, Volkan OZENCI, Robert KRAUSE, Matteo BASSETTI, Laura LOUGHLIN, Blandine DENIS, Anna GRANCINI, P Lewis WHITE, Katrien LAGROU, Birgit WILLINGER, Riina RAUTEMAA-RICHARDSON, Petr HAMAL, Beyza ENER, Tugce UNALAN-ALTINTOP, Ebru EVREN, Suleyha HILMIOGLU-POLAT, Yasemin OZ, Ozlem Koyuncu OZYURT, Faruk AYDIN, Filip RŮŽIČKA, Eelco F J MEIJER, Jean Pierre GANGNEUX, Deborah E A LOCKHART, Nina KHANNA, Clare LOGAN, Ulrike SCHARMANN, Guillaume DESOUBEAUX, Emmanuel ROILIDES, Alida Fe TALENTO, van Dijk KARIN, Philipp KOEHLER, Jon SALMANTON-GARCIA, Oliver A CORNELY and Martin HOENIGL. European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study. JOURNAL OF INFECTION. LONDON: W B SAUNDERS CO LTD, 2023, vol. 87, No 5, p. 428-437. ISSN 0163-4453. Available from: https://dx.doi.org/10.1016/j.jinf.2023.08.001.

@article{2368998,
 author = {Arendrup, Maiken Cavling and ArikanandAkdagli, Sevtap and Jorgensen, Karin Meinike and Barac, Aleksandra and Steinmann, Jorg and Toscano, Cristina and Arsenijevic, Valentina Arsic and Sartor, Assunta and LassandFloerl, Cornelia and Hamprecht, Axel and Matos, Tadeja and Rogers, Benedict R S and Quiles, Inmaculada and Buil, Jochem and Ozenci, Volkan and Krause, Robert and Bassetti, Matteo and Loughlin, Laura and Denis, Blandine and Grancini, Anna and White, P Lewis and Lagrou, Katrien and Willinger, Birgit and RautemaaandRichardson, Riina and Hamal, Petr and Ener, Beyza and UnalanandAltintop, Tugce and Evren, Ebru and HilmiogluandPolat, Suleyha and Oz, Yasemin and Ozyurt, Ozlem Koyuncu and Aydin, Faruk and Růžička, Filip and Meijer, Eelco F J and Gangneux, Jean Pierre and Lockhart, Deborah E A and Khanna, Nina and Logan, Clare and Scharmann, Ulrike and Desoubeaux, Guillaume and Roilides, Emmanuel and Talento, Alida Fe and Karin, van Dijk and Koehler, Philipp and SalmantonandGarcia, Jon and Cornely, Oliver A and Hoenigl, Martin},
 article_location = {LONDON},
 article_number = {5},
 doi = {http://dx.doi.org/10.1016/j.jinf.2023.08.001},
 keywords = {Candida; C. parapsilosis; Fluconazole resistance; Echinocandin resistance; Fks1; EUCAST},
 language = {eng},
 issn = {0163-4453},
 journal = {JOURNAL OF INFECTION},
 title = {European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study},
 url = {https://www.sciencedirect.com/science/article/pii/S0163445323004516?via%3Dihub},
 volume = {87},
 year = {2023}
}

TY - JOUR
ID - 2368998
AU - Arendrup, Maiken Cavling - Arikan-Akdagli, Sevtap - Jorgensen, Karin Meinike - Barac, Aleksandra - Steinmann, Jorg - Toscano, Cristina - Arsenijevic, Valentina Arsic - Sartor, Assunta - Lass-Floerl, Cornelia - Hamprecht, Axel - Matos, Tadeja - Rogers, Benedict R S - Quiles, Inmaculada - Buil, Jochem - Ozenci, Volkan - Krause, Robert - Bassetti, Matteo - Loughlin, Laura - Denis, Blandine - Grancini, Anna - White, P Lewis - Lagrou, Katrien - Willinger, Birgit - Rautemaa-Richardson, Riina - Hamal, Petr - Ener, Beyza - Unalan-Altintop, Tugce - Evren, Ebru - Hilmioglu-Polat, Suleyha - Oz, Yasemin - Ozyurt, Ozlem Koyuncu - Aydin, Faruk - Růžička, Filip - Meijer, Eelco F J - Gangneux, Jean Pierre - Lockhart, Deborah E A - Khanna, Nina - Logan, Clare - Scharmann, Ulrike - Desoubeaux, Guillaume - Roilides, Emmanuel - Talento, Alida Fe - Karin, van Dijk - Koehler, Philipp - Salmanton-Garcia, Jon - Cornely, Oliver A - Hoenigl, Martin
PY - 2023
TI - European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study
JF - JOURNAL OF INFECTION
VL - 87
IS - 5
SP - 428-437
EP - 428-437
PB - W B SAUNDERS CO LTD
SN - 01634453
KW - Candida
KW - C. parapsilosis
KW - Fluconazole resistance
KW - Echinocandin resistance
KW - Fks1
KW - EUCAST
UR - https://www.sciencedirect.com/science/article/pii/S0163445323004516?via%3Dihub
N2 - The objectives of this study were to assess Candida spp. distribution and antifungal resistance of candi-daemia across Europe. Isolates were collected as part of the third ECMM Candida European multicentre observational study, conducted from 01 to 07-07-2018 to 31-03-2022. Each centre (maximum number/ country determined by population size) included-10 consecutive cases. Isolates were referred to central laboratories and identified by morphology and MALDI-TOF, supplemented by ITS-sequencing when needed. EUCAST MICs were determined for five antifungals. fks sequencing was performed for echinocandin re-sistant isolates. The 399 isolates from 41 centres in 17 countries included C. albicans (47.1%), C. glabrata (22.3%), C. parapsilosis (15.0%), C. tropicalis (6.3%), C. dubliniensis and C. krusei (2.3% each) and other species (4.8%). Austria had the highest C. albicans proportion (77%), Czech Republic, France and UK the highest C. glabrata proportions (25-33%) while Italy and Turkey had the highest C. parapsilosis proportions (24-26%). All isolates were amphotericin B susceptible. Fluconazole resistance was found in 4% C. tropicalis, 12% C. glabrata (from six countries across Europe), 17% C. parapsilosis (from Greece, Italy, and Turkey) and 20% other Candida spp. Four isolates were anidulafungin and micafungin resistant/non-wild-type and five resistant to micafungin only. Three/3 and 2/5 of these were sequenced and harboured fks-alterations including a novel L657W in C. parapsilosis. The epidemiology varied among centres and countries. Acquired echinocandin resistance was rare but included differential susceptibility to anidulafungin and micafungin, and resistant C. parapsilosis. Fluconazole and voriconazole cross-resistance was common in C. glabrata and C. parapsilosis but with different geographical prevalence.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ER -

ARENDRUP, Maiken Cavling, Sevtap ARIKAN-AKDAGLI, Karin Meinike JORGENSEN, Aleksandra BARAC, Jorg STEINMANN, Cristina TOSCANO, Valentina Arsic ARSENIJEVIC, Assunta SARTOR, Cornelia LASS-FLOERL, Axel HAMPRECHT, Tadeja MATOS, Benedict R S ROGERS, Inmaculada QUILES, Jochem BUIL, Volkan OZENCI, Robert KRAUSE, Matteo BASSETTI, Laura LOUGHLIN, Blandine DENIS, Anna GRANCINI, P Lewis WHITE, Katrien LAGROU, Birgit WILLINGER, Riina RAUTEMAA-RICHARDSON, Petr HAMAL, Beyza ENER, Tugce UNALAN-ALTINTOP, Ebru EVREN, Suleyha HILMIOGLU-POLAT, Yasemin OZ, Ozlem Koyuncu OZYURT, Faruk AYDIN, Filip RŮŽIČKA, Eelco F J MEIJER, Jean Pierre GANGNEUX, Deborah E A LOCKHART, Nina KHANNA, Clare LOGAN, Ulrike SCHARMANN, Guillaume DESOUBEAUX, Emmanuel ROILIDES, Alida Fe TALENTO, van Dijk KARIN, Philipp KOEHLER, Jon SALMANTON-GARCIA, Oliver A CORNELY and Martin HOENIGL. European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM\&{}lt;i\&{}gt; Candida\&{}lt;/i\&{}gt; III study. \textit{JOURNAL OF INFECTION}. LONDON: W B SAUNDERS CO LTD, 2023, vol.~87, No~5, p.~428-437. ISSN~0163-4453. Available from: https://dx.doi.org/10.1016/j.jinf.2023.08.001.

Detailed Information on Publication Record

European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM<i> Candida</i> III study